Abstract: Schizophrenia is a complex and disabling psychiatric disorder, and tardive dyskinesia (TD) is a severe adverse drug effect occurring in 20% to 40% of schizophrenic patients chronically treated with typical neuroleptics. Previous studies suggested that the manganese superoxide dismutase (MnSOD) activity was associated with the development of schizophrenia. Ala-9Val polymorphism, a functional polymorphism of MnSOD gene, has been reported to be related to the risk of schizophrenia and TD. However, these studies did not lead to consistent results. We performed meta-analyses aiming to assess the association between MnSOD activity and schizophrenia, as well as the association of MnSOD Ala-9Val polymorphism with schizophrenia and TD in schizophrenic patients.
INTRODUCTION

S
chizophrenia is a complex and disabling psychiatric disorder characterized by psychopathology, cognition, and neurobiological abnormality abnormalities, with deficits in perception, emotion, and social behavior. 1, 2 Although the pathogenesis of schizophrenia is not fully understood, the alteration of the oxidative stress, an imbalance between free radical metabolism and the antioxidant defense system, has been suggested to be associated with the development of schizophrenia. 3 The superoxide dismutases (SODs) are 1 group of the key antioxidant defense enzymes playing a crucial role in preventing cell oxidative damage from free radicals. 4 Among 3 isoforms of SODs, the manganese superoxide dismutase (MnSOD), the intramitochondrial SOD, is the main antioxidant enzyme playing a critical role in the detoxification of superoxide radicals. 5, 6 Although it has been demonstrated that altered total SOD activity existed in schizophrenic patients, the studies on the association between MnSOD activity and schizophrenia were limited and conflicting. [7] [8] [9] [10] [11] [12] The MnSOD gene known as a candidate region for linkage with schizophrenia is located in chromosome 6q25. 13 Among known functional polymorphisms of the MnSOD gene, the Ala9Val polymorphism in exon 2 is the most widely investigated SNP, with the Ala-to-Val substitution possibly leading to the alteration of MnSOD activity in human mitochondria. 13, 14 Studies on the association between Ala-9Val polymorphism and schizophrenia generated inconsistent results in different ethnic groups. 10, 11, [15] [16] [17] [18] Tardive dyskinesia (TD) is a severe adverse drug effect occurring in 20% to 40% of schizophrenic patients chronically treated with typical neuroleptics, characterized by the delayed manifestation of involuntary movements. 19, 20 Several studies investigated the genetic association between the MnSOD Ala9Val variants and TD, but the results were inconsistent. 10, 15, 17, [21] [22] [23] [24] [25] Recently, a meta-analysis performed by Zai et al 26 did not reveal a significant association of Ala-9Val alleles or genotypes with the risk of TD in schizophrenic patients. However, this study neither included entire references nor found the sources of high heterogeneity.
Therefore, we carried out this meta-analysies to further assess the association between MnSOD Ala-9Val polymorphism and TD in schizophrenic patients, and also to evaluate the association between MnSOD activity, MnSOD Ala-9Val polymorphism, and schizophrenia.
METHODS
Ethical Review
Meta-analysis does not involve ethical review.
Search Strategy
We conducted literature search on MnSOD and schizophrenia in English or Chinese published up to May 1, 2015. PubMed, EMBASE, the Cochrane Databases, Chinese National Knowledge Infrastructure, and China Biology Medical and Wanfang databases were searched by 2 researchers independently. The following terms were used: ''manganese superoxide dismutase OR superoxide dismutase 2 OR SOD2 OR MnSOD'' AND ''schizophrenia OR psychotic disorders OR psychosis.'' We also searched the reference lists of the retrieved articles and reviews for additional articles.
Criteria for Inclusion and Exclusion
Studies were included if they met the following criteria: a case-control study (schizophrenia patients vs healthy controls or patients with TD vs ones without TD) or cohort study was performed; the diagnosis of schizophrenia was conducted according to Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria or Chinese Classification of Mental Disorders (CCMD); the presence of TD was assessed using the Abnormal Involuntary Movement Scale (AIMS) or the modified Hillside Simpson Dyskinesia Scale (HSDS); data on MnSOD activity of schizophrenia patients and healthy controls, or MnSOD Ala-9Val genotypes and alleles of schizophrenic patients and healthy controls, or MnSOD Ala-9Val genotypes and alleles of schizophrenic patients with TD and without TD were available.
The exclusion criteria were: the studies were not related to MnSOD or schizophrenia; the studies did not provide sufficient information about MnSOD activity or MnSOD Ala-9Val genotype and allele frequencies; the genotypic distributions of MnSOD Ala-9Val gene in healthy controls were inconsistent with Hardy-Weinberg equilibrium (HWE) in the meta-analysis of the association between MnSOD Ala-9Val polymorphism and schizophrenia; the references used overlapping datasets with the included studies.
We used the Newcastle-Ottawa Quality Assessment Scale to assess the quality of studies included in the meta-analysis.
Data Extraction
Data were extracted from the included studies using a standardized data extraction form by 2 reviewers independently, and any discrepancy was discussed and resolved by consensus with a third reviewer. The extracted information included the followings: the first author, the publication year, country, geographic location, the mean age and gender ratio (female/male), diagnostic criteria, specimen, assay method of MnSOD activity, genotyping method, duration of illness (years), sample size, mean, and standard deviation (SD) of MnSOD activity (U/mL) of the case and control groups, Ala-9Val genotype and allele frequencies of cases with TD and without TD as well as the control group.
Outcomes Measures
We performed separate meta-analyses comparing: MnSOD activity between schizophrenic patients and healthy controls; MnSOD Ala-9Val genotype and allele distribution between schizophrenic patients and healthy controls; MnSOD Ala-9Val genotype and allele distribution between schizophrenic patients with TD and without TD.
Statistical Analysis
The meta-analysis on the association between the MnSOD activity and schizophrenia was carried out by pooled standardized mean differences (SMD) with 95% confidence interval (95% CI). The meta-analyses on the association of the MnSOD Ala-9Val polymorphism with schizophrenia and TD were performed using recessive genetic model (Ala/Ala and Ala/Val vs Val/Val) and allele frequency (Ala vs Val), and the pooled odds ratio (OR) and 95% CI were calculated. Heterogeneity among studies was estimated using the Cochran Q and I 2 statistic. For the Q statistic, P < 0.10 indicates statistically significant heterogeneity. For the I 2 statistic, I 2 > 50% indicates a large heterogeneity. A fixed-effect model with Mantel-Haenszel method was used if Q statistic (P < 0.10) or I 2 < 50%. Otherwise, a random-effect model was used. In case of heterogeneity, metaregression analysis or subgroup analysis was conducted. Sensitivity analysis was performed to strengthen the result of the meta-analysis. Publication bias was assessed using the Begg's and Egger's tests. All data analyses were performed using Stata 12.0 (Stata Corp LP, College Station, TX).
RESULTS
Basic Information of the Included Studies
The process of identifying eligible articles was summarized in Figure 1 . The meta-analysis of the association between MnSOD activity and schizophrenia included 6 studies involving 1541 (61.1%) schizophrenic patients and 981 (38.9%) healthy controls which were all Chinese subjects (Table 1) . For the meta-analysis of the association between Ala-9Val polymorphism and schizophrenia, 6 studies were included and most of them were from Asia (66.7%, 4/6), with a total of 1976 (56.5%) patients and 1520 (43.5%) controls (Table 2) . Table 3 showed the information of 10 included studies for the meta-analysis of the association between Ala-9Val polymorphism and TD in schizophrenic patients. Totally, there were 676 (32.1%) patients with TD and 1427(67.9%) ones without TD. Most of the studies were from Asia (70.0%, 7/10). All studies received a score of !6, indicating good qualities.
The MnSOD Activity and Schizophrenia Risk
The random-effect model showed that the MnSOD activity of patients was significantly lower than that of controls (SMD ¼ À0.94; 95% CI: À1.76, À0.12; P ¼ 0.025) with significant heterogeneity among studies (I 2 ¼ 98.4%, P < 0.001) (Figure 2) .
We performed subgroup analysis to analyze the sources of heterogeneity ( Figure S1 , http://links.lww.com/MD/A410). Five factors were used for subgroup analysis, including mean age of the case group ( 50/>50 years), gender ratio (female/ male ¼ 0/>1), sample type (serum/plasma), published year (before 2010/after 2010), and duration of illness ( 30/>30 years) ( Figure S1 , http://links.lww.com/MD/A410). However, the heterogeneity still kept high (>90%) in all the subgroups. No evidence of publication bias were observed in the included studies (P Egger ¼ 0.357 and P Begg ¼ 0.851) ( Figure S2 , http:// links.lww.com/MD/A410).
The Association Between MnSOD Ala-9Val Polymorphism and Schizophrenia Risk
The genotypic as well as allelic analysis using the fixedeffect model, did not show significant associations of Ala-9Val genotypes (OR ¼ 1.14; 95% CI: 0.97, 1.33; P ¼ 0.109) and alleles (OR ¼ 1.06; 95% CI: 0.94, 1.20; P ¼ 0.361) with the risk of schizophrenia (Figure 3 ). There were no evidence for heterogeneity among the studies for both genotypes (I 2 ¼ 0.0%, P ¼ 0.696) and alleles (I 2 ¼ 0.0%, P ¼ 0.579). In the sensitivity analyses, each included study was removed one by one to determine the effect of an individual The quality score was evaluated by the Cochrane's Newcastle-Ottawa Scale evaluation standard for case-control study. The quality score was evaluated by the Cochrane's Newcastle-Ottawa Scale evaluation standard for case-control study. 
The Association Between MnSOD Ala-9Val Polymorphism and TD in Schizophrenia Patients
The random-effect model did not show the significant association between Ala-9Val genotypes and the risk of TD in schizophrenia (OR ¼ 0.82; 95% CI: 0.66, 1.02; P ¼ 0.075) with a heterogeneity of I 2 ¼ 39.5% (P ¼ 0.095) among studies ( Figure 4A ). There was no significant association between Ala9Val alleles and TD (OR ¼ 0.90; 95% CI: 0.76, 1.06; P ¼ 0.215) with no heterogeneity among studies (I 2 ¼ 23.6%, P ¼ 0.226) by the fixed-effect model ( Figure 4B ).
Meta-regression was performed further to explore the possible sources of the heterogeneity for genotypes results. We put 4 factors into the meta-regression model. As shown in Table 4 , none of these factors had any significant influence on the genotypes results (P > 0.05). We further conducted subgroup analysis, observing a light decrease of heterogeneity in the subgroups of geographic location ( Figure S5B , http:// links.lww.com/MD/A410).
The sensitivity analysis indicated stability and reliability of results for the associations of MnSOD Ala-9Val genotypes and alleles with TD ( Figure S6 
DISCUSSION
In our meta-analyses, the significant association was observed between MnSOD activity and chronic schizophrenia in Chinese population. However, no statistically significant associations were observed between MnSOD Ala-9Val polymorphism and schizophrenia as well as TD.
It has been reported that the SOD activity was decreased in chronic schizophrenic patients while increased in first-episode schizophrenic patients. 27 However, studies on the association between MnSOD activity and schizophrenia were limited, most of which indicated that MnSOD activity of schizophrenia patients was lower than that of controls. To our knowledge, this is the first study to conduct a meta-analysis focusing on MnSOD activity in schizophrenia. We found that MnSOD activity was significantly decreased in Chinese population with chronic schizophrenia, which was consistent with the result of the total SOD activity. MnSOD is a main antioxidant enzyme scavenging the greatest number of superoxide anions produced by mitochondrial energy metabolism, 5 and also plays a significant role in neurodevelopment. 28 Lower MnSOD activity in schizophrenic patients may reflect an imbalance between free radical production and antioxidant levels in schizophrenia. However, these included studies all focused on Chinese patients of chronic type, so further researches on other populations of different ethnicities and first-episode patients were needed to evaluate the association between MnSOD activity and schizophrenia. Apart from some factors we considered in this study, the high heterogeneity among the included studies may be due to some other factors such as the type and daily dose of antipsychotics, duration of treatment, the subtypes of patients recruited, and so forth.
The MnSOD gene contains a functional polymorphism Ala-9Val in the mitochondrial targeting sequence, of which the Val allele induces a conformational change in the mitochondrial targeting sequence and misdirects intracellular trafficking of the protein. 6, 29 The presence of this allele may result in decreased capacity of detoxification of the harmful superoxide radicals. Most of previous studies suggested that the MnSOD Ala-9Val polymorphism might not directly contribute to the risk of schizophrenia and TD. However, the study by Zhang et al 11 showed a protective effect for the Val/Val genotype on schizophrenia in Chinese population, while Hori et al 15 and Akyol et al 22 found that Ala allele played a role in protecting against susceptibility to TD in Japanese schizophrenic patients. Our meta-analyses did not reveal significant associations of the alleles or genotypes with schizophrenia and TD in schizophrenia, which is consistent with the study by Zai et al. 26 It is likely due to the complex interaction between multiple genetic and environmental factors, and insufficient sample size which failed to detect small genetic effect sizes.
It is noteworthy that the Val/Val genotype and Val allele frequencies were higher in most Asian populations compared to those in other ethnicities, and the general heterogeneity among the studies on genotypes and TD association witnessed a light decline in the subgroups from different geographic locations, although meta-regression did not indicate a significant influence of the geographic location on our results. Therefore, replications in different ethnicities are needed since the genetic vulnerability may have effects on the development of schizophrenia or TD in different ethnic populations.
There are some limitations in our study. The references included in our study may not be comprehensive, since we failed to obtain the articles apart from English and Chinese publications. We only acquired the data of MnSOD activity in Chinese population since studies about other populations all focused on the activity of total SOD. Therefore, the extrapolation of the association between the MnSOD activity and schizophrenia to other populations may be limited. The high heterogeneity among the studies for MnSOD activity was not resolved due to lack of details of some other factors such as antipsychotics type.
In summary, our meta-analyses indicated that the decreased MnSOD activity may be associated with the risk of chronic schizophrenia in Chinese population, while the MnSOD Ala-9Val polymorphism may not play a significant role in the development of schizophrenia and TD. Longitudinal studies with larger sample sizes and different ethnicities are needed, and interaction between multiple genetic and environmental factors should be considered to confirm the association of the MnSOD Ala-9Val variants with schizophrenia and TD. 
